Biocryst Pharmaceuticals (BCRX) Change in Cash (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has 17 years of Change in Cash data on file, last reported at $82.0 million in Q1 2026.

• Quarterly Change in Cash rose 14602.69% year-over-year to $82.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.5 million (up 220.47% YoY) and the FY2025 annual result came in at -$15.0 million, down 144.71% from the prior year.
• Change in Cash rose to $82.0 million in Q1 2026, from -$9.6 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $82.0 million in Q1 2026 to a low of -$149.6 million in Q1 2023.
• A 5-year average of -$19.7 million and a median of -$5.9 million in 2024 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2022 — Change in Cash slumped 668.33% — and 2026, when it jumped 14602.69%.
• Tracing BCRX's Change in Cash over 5 years: stood at $57.9 million in 2022, then slumped by 169.16% to -$40.0 million in 2023, then jumped by 118.13% to $7.3 million in 2024, then slumped by 231.7% to -$9.6 million in 2025, then jumped by 958.17% to $82.0 million in 2026.
• The last three Change in Cash figures came in at $82.0 million (Q1 2026), -$9.6 million (Q4 2025), and -$4.1 million (Q3 2025), per Business Quant data.